Chiesi UK & Ireland has published new research revealing significant gaps in the understanding and practice of inhaler use among UK asthma patients. The study published in the BMJ Open Respiratory ...

Chiesi GRD has an initial focus in developing therapies for lysosomal storage disorders (LSDs), including Fabry disease, as well as other rare diseases in haematology and opthalmology indications.

Located on the outskirts of the historic Italian city – home to Verdi and myriad architectural gems – the press launch and tour of the €85 million Chiesi development was a quintessentially ...

Since opening its doors in 1981, Nohra Haime Gallery has been recognized for its consistent representation of International, Latin American, sculpture and women artists, often exhibiting work that ...

Tanimilast is under clinical development by Chiesi Farmaceutici and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) ...